Research programme: CAR T cell therapies - Coeptis Therapeutics
Alternative Names: Research programme: CAR T cell therapies - Coeptis Therapeutics/University of Pittsburgh; SNAP-CAR NK cell therapy - Coeptis TherapeuticsLatest Information Update: 15 May 2024
At a glance
- Originator Coeptis Therapeutics
 - Developer Coeptis Therapeutics; University of Pittsburgh
 - Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
 - Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity No
 
Highest Development Phases
- Preclinical Solid tumours
 - Research Autoimmune disorders